Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
28,862,345
-
Total 13F shares
-
16,787,790
-
Share change
-
+185,170
-
Total reported value
-
$1,189,003,666
-
Put/Call ratio
-
77%
-
Price per share
-
$70.83
-
Number of holders
-
179
-
Value change
-
+$7,018,079
-
Number of buys
-
92
-
Number of sells
-
87
Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q4 2018
As of 31 Dec 2018,
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) was held by
179 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,787,790 shares.
The largest 10 holders included
BlackRock Inc., Vanguard Group Inc, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, FARALLON CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, JANUS HENDERSON GROUP PLC, FIRST MANHATTAN CO, DIMENSIONAL FUND ADVISORS LP, and Krensavage Asset Management, LLC.
This page lists
179
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.